A detailed history of Ubs Group Ag transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 417,705 shares of ADMA stock, worth $8.93 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
417,705
Previous 373,937 11.7%
Holding current value
$8.93 Million
Previous $4.18 Million 99.74%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$11.21 - $20.03 $490,639 - $876,673
43,768 Added 11.7%
417,705 $8.35 Million
Q2 2024

Aug 13, 2024

SELL
$5.98 - $11.18 $1.15 Million - $2.14 Million
-191,494 Reduced 33.87%
373,937 $4.18 Million
Q1 2024

May 13, 2024

BUY
$4.4 - $6.74 $295,380 - $452,469
67,132 Added 13.47%
565,431 $3.73 Million
Q4 2023

Feb 09, 2024

BUY
$3.08 - $4.52 $832,092 - $1.22 Million
270,160 Added 118.42%
498,299 $2.25 Million
Q3 2023

Nov 09, 2023

SELL
$3.47 - $4.61 $193,650 - $257,270
-55,807 Reduced 19.65%
228,139 $816,000
Q2 2023

Aug 11, 2023

SELL
$3.12 - $4.22 $312,324 - $422,438
-100,104 Reduced 26.07%
283,946 $1.05 Million
Q1 2023

May 12, 2023

SELL
$3.01 - $3.87 $476,958 - $613,232
-158,458 Reduced 29.21%
384,050 $1.27 Million
Q4 2022

Feb 08, 2023

BUY
$2.47 - $3.88 $1.18 Million - $1.86 Million
479,078 Added 755.29%
542,508 $2.1 Million
Q3 2022

Nov 10, 2022

BUY
$2.03 - $2.86 $128,762 - $181,409
63,430 New
63,430 $154,000
Q2 2022

Aug 10, 2022

SELL
$1.43 - $2.2 $16,294 - $25,069
-11,395 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$1.28 - $1.83 $14,585 - $20,852
11,395 New
11,395 $21,000
Q4 2021

Feb 14, 2022

SELL
$1.09 - $1.66 $20,094 - $30,602
-18,435 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$1.13 - $1.65 $15,209 - $22,209
13,460 Added 270.55%
18,435 $21,000
Q2 2021

Aug 13, 2021

SELL
$1.51 - $2.07 $23,311 - $31,956
-15,438 Reduced 75.63%
4,975 $8,000
Q1 2021

May 12, 2021

SELL
$1.67 - $2.95 $2,443 - $4,315
-1,463 Reduced 6.69%
20,413 $36,000
Q4 2020

Feb 11, 2021

BUY
$1.8 - $2.56 $31,903 - $45,373
17,724 Added 426.88%
21,876 $43,000
Q3 2020

Nov 12, 2020

SELL
$2.04 - $3.74 $67,295 - $123,375
-32,988 Reduced 88.82%
4,152 $10,000
Q2 2020

Jul 31, 2020

BUY
$2.42 - $3.29 $5,338 - $7,257
2,206 Added 6.31%
37,140 $109,000
Q1 2020

May 01, 2020

SELL
$1.5 - $4.59 $34,111 - $104,381
-22,741 Reduced 39.43%
34,934 $100,000
Q4 2019

Feb 14, 2020

SELL
$3.89 - $5.15 $25,475 - $33,727
-6,549 Reduced 10.2%
57,675 $231,000
Q3 2019

Nov 14, 2019

BUY
$3.19 - $5.39 $188,927 - $319,222
59,225 Added 1184.74%
64,224 $286,000
Q2 2019

Aug 14, 2019

BUY
$3.52 - $5.24 $12,584 - $18,733
3,575 Added 251.05%
4,999 $19,000
Q1 2019

May 14, 2019

SELL
$2.61 - $4.35 $911,537 - $1.52 Million
-349,248 Reduced 99.59%
1,424 $5,000
Q4 2018

Feb 14, 2019

BUY
$2.17 - $6.12 $746,623 - $2.11 Million
344,066 Added 5208.39%
350,672 $838,000
Q3 2018

Nov 14, 2018

SELL
$4.39 - $6.85 $588 - $917
-134 Reduced 1.99%
6,606 $41,000
Q2 2018

Aug 14, 2018

BUY
$4.39 - $5.44 $16,098 - $19,948
3,667 Added 119.33%
6,740 $30,000
Q1 2018

May 15, 2018

BUY
$3.21 - $5.21 $9,864 - $16,010
3,073 New
3,073 $14,000
Q4 2017

Feb 14, 2018

SELL
$2.06 - $3.24 $7,004 - $11,016
-3,400 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$2.76 - $3.71 $9,384 - $12,614
3,400
3,400 $10,000

Others Institutions Holding ADMA

About ADMA BIOLOGICS, INC.


  • Ticker ADMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 196,356,992
  • Market Cap $4.2B
  • Description
  • ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...
More about ADMA
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.